Opioid Use Disorder Market Expected to Reach $8.1 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Opioid Use Disorder Market," The opioid use disorder market size was valued at $2.8 billion in 2021, and is estimated to reach $8.1 billion by 2031, growing at a CAGR of 11.5% from 2022 to 2031. Opioids are produced synthetically or naturally in laboratories to mimic the chemical features of opioids that interact with opioid receptors on nerve cells in the body and brain to alleviate pain. They are a group of substances that also includes heroin, synthetic opioids, and prescription painkillers. Prescription opioids are intended to be used to manage acute pain, such as that experienced after an injury or surgery, chronic pain, cancer that is actively being treated, palliative care, and end-of-life care. Many patients who are being treated by a doctor rely on prescribed opioids to help them manage their problems. Opioid use disorder is a chronic, lifelong condition with grave potential outcomes, such as disability, relapses, and death. 

Factors that drive the opioid use disorder market growth include increase in cases of opioid addiction, and rise in number of opioid industry. Rise in numbers of people are afflicted with a variety of severe and chronic diseases, including cancer, cardiovascular disease, pain from injuries, and other illnesses. Chronic pain is a common side effect of many disorders, which is frequently treated with opioid medicines. The patient is more likely to develop a drug addiction even while the discomfort is reduced. Withdrawal symptoms could develop in the patient as a result of the increasing dependence and sudden termination of the medications. In addition, the healthcare industry in emerging economies is developing at a significant rate, owing to surge in demand for better healthcare services and significant rise in research & development activities for opioids in treatment of chronic pain. For instance, according to the National Center of Biotechnology Information (NCBI), it was estimated that around five billion people suffered from chronic pain in 2021. 

Moreover, according to Centre for Disease Control and Prevention, in 2019, it was reported that opioids were involved in 49,860 overdose death in U.S. In addition, according to the National Institute of Drug Abuse, more than 130 people in the U.S. die daily due to overdosing of opioids. Thus, rise in cases of opioid addiction anticipated to fuel the growth of opioid use disorder market. Moreover, rise in product launch and product approval for opioid use disorder drugs anticipated to fuel the growth of market. For instance, in May 2020, Indivior PLC, a pharmaceutical company, announced the approval of Subutex from Swedish Medical Products Agency (MPA). Subutex prolonged release solution for injection, 100 and 300mg for substitution treatment of opioid dependence in adults and adolescents over 16 years of age. Moreover, in February 2019, Dr. Reddy's Laboratories, a pharmaceutical company, announced the re-launch of buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent generic version of Suboxone sublingual film, in the United States market. Buprenorphine is agonist type of opioids use disorders drug. 

Moreover, rise in number of surgical procedures, chronic cardiovascular diseases, cancer is anticipated to fuel the opioid use disorder market trends. Increase in number of surgical procedures cause rise in the use of opioid for pain management after surgery. It causes rise in prevalence of addition to opioids which is anticipated to cause opioids use disorder. Thus, this factor is anticipated to fuel the market growth. Moreover, increase in the prevalence of chronic diseases, cardiovascular diseases, and cancer lead to increase in the number of surgeries associated with post-surgical pain. Therefore, this factor fuels the market growth. For instance, according to the Centers for disease control and prevention (CDC) approximately 659,000 population in the U.S. experienced death from heart disease each year. According to the same report in 2019, a total of 360,900 people died due to coronary heart disease. 
Every year in the U.S. approximately 805,000 population are diagnosed with heart attack among which 605,000 experienced their first heart attack. This factor upsurges the need for heart surgery, which further increases the need for opioids to relive post-surgical pain. Thus, this factor drives the growth of the opioids use disorder market. 

On the basis of type, the opioid use disorder market share is segmented into agonist and antagonist. The agonist segment dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to rise in the prevalence of chronic pain, high prevalence of opioid abuse and rising geriatric population prone to painful disease.

On the basis of age group, the market is classified into 19 to 39, 40 to 59 and age 60 and over. The 19 to 39 segment dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to rise in the prevalence of chronic diseases such as cancer, cardiovascular diseases and orthopedic diseases associated with chronic pain. 

On the basis of route of administration, the market is classified into oral, intravenous and sublingual. The intravenous dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to buprenorphine is agonist type of opioids use disorder drug which is used by sublingual route for administration purpose, rise in the demand of buprenorphine for the treatment of opioids use disorder treatment.

On the basis of distribution channel, the market is divided into hospital pharmacy and retail pharmacy. The hospitals segment dominated the market in 2021, and is expected to remain dominant during the forecast period, owing to rise in number of hospital pharmacies, increase in expenditure by government to develop healthcare infrastructure and increase in the prevalence of opioids use disorder.

The North America market was dominant, in terms of revenue among other regions in 2021, owing to increase the number of product launch, and product approval for opioids use disorder, increase in the prevalence of chronic diseases such as cancer, cardiac diseases and orthopedic diseases and well-established healthcare infrastructure in North America. On the other hand, Asia-Pacific was the second-largest contributor in the market in 2021, and is expected to register fastest CAGR during the forecast period, owing rise in the geriatric populations, rise in the awareness regarding availability of healthcare services and increase in the number of chronic diseases. 

Key Findings Of The Study
•    By type, the agonist segment was the highest contributor to the market in 2021.
•    By age group, the 19 to 39 segment was the highest contributor to the market in 2021.
•    By route of administration, the intravenous segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
•    By distribution channel, the hospital pharmacy segment dominated the market in 2021, and is expected to continue this trend during the forecast period.
•    By region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.